First real-world data provide evidence for a 'window of opportunity' in treatment of hidradenitis suppurativa/acne inversa
- PMID: 32476130
- DOI: 10.1111/bjd.19165
First real-world data provide evidence for a 'window of opportunity' in treatment of hidradenitis suppurativa/acne inversa
Comment on
-
Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.Br J Dermatol. 2021 Jan;184(1):133-140. doi: 10.1111/bjd.18983. Epub 2020 Apr 13. Br J Dermatol. 2021. PMID: 32119111
References
-
- Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther 2019; 106:36.
-
- McDonald L, Lambrelli D, Wasiak R, Ramagopalan SV. Real-world data in the U.K.: opportunities and challenges. BMC Med 2016; 14:97.
-
- Eichler HG, Koenig F, Arlett P et al. Are novel, nonrandomized analytic methods fit for decision-making? The need for prospective, controlled, and transparent validation. Clin Pharmacol Ther 2020; 107:773-9.
-
- Corboy JR. Real-world practice. Neurol Clin Pract 2018; 8:275.
-
- Tzellos T, Zouboulis CC. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther (Heidelb) 2020; 10:63-71.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical